Abstract:Glucagon‐like peptide‐1 receptor agonists for pediatric metabolic dysfunction associated steatotic liver disease. Pediatric obesity, characterized by a body mass index (BMI) at or above the 95th percentile for age, affects a substantial number of children and adolescents worldwide. Metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, represents a prominent hepatic manifestation of obesity and metabolic syndrome, emerging as the most prevalent hepatic disorder among pediatric patients and a significant contributor to liver transplantation in adults. The escalating prevalence of pediatric MASLD mirrors the alarming rise in childhood obesity rates over recent decades. While lifestyle modifications focusing on dietary changes and increased physical activity constitute the cornerstone of MASLD management, achieving and maintaining significant weight reduction remains challenging. Moreover, disease progression often persists despite standard‐of‐care interventions, warranting exploration into alternative therapeutic strategies. Pharmacological interventions, particularly, glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), have shown promise in addressing pediatric obesity and its associated comorbidities, including MASLD. Recent studies have demonstrated the efficacy of GLP‐1RA in inducing weight loss and improving liver enzyme levels, suggesting a potential role in halting disease progression, and reducing the risk of major adverse liver outcomes. This review provides a comprehensive overview of the current pharmacotherapy landscape for pediatric MASLD, with a focus on novel agents such as GLP‐1RA. Furthermore, the manuscript proposes a practical algorithm to assist in integrating GLP‐1RA into the clinical management of pediatric patients with obesity and MASLD. Despite promising results, further research is warranted to elucidate the long‐term efficacy and safety of GLP‐1RA in pediatric populations.

The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic- Dysfunction Associated Steatohepatitis

The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis

Incretin-based investigational therapies for the treatment of MASLD/MASH

Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)

Drug treatment for MASLD: Progress and direction

Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence

Novel Medication in New Liver Disease Nomenclature

Therapeutic management of metabolic dysfunction associated steatotic liver disease

Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease

Current Progress and Challenges in the Development of Pharmacotherapy for Metabolic Dysfunction‐Associated Steatohepatitis

FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond

Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments

Glucagon-like Peptide-1 Receptor Agonists—A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)

Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists

Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis

Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: A prospective cohort study

S1768 The Efficacy of GLP-1 Agonists in the Management of MASH in an Appalachian Cohort